Want to see AU:HMD full AI Analyst Report?

HeraMED Ltd. (HMD) Price & Analysis

4 Followers

HMD Stock Chart & Stats

AU$0.04

AU$0.00(0.00%)

At close: Jan 08 4:00 PM EST

AU$0.04

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.06

Previous CloseN/A

Volume370.09K

Average Volume (3M)1.96M

Market Cap

AU$42.87M

Enterprise ValueAU$19.93M

Total Cash (Recent Filing)AU$914.65K

Total Debt (Recent Filing)AU$282.39K

Price to Earnings (P/E)―

Beta1.95

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,158,636,600

10 Day Avg. Volume1,195,844

30 Day Avg. Volume1,958,766

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)41.38

Price to Sales (P/S)131.32

P/FCF Ratio-10.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet / Zero DebtThe company's deleveraging to zero reported debt and small positive equity reduces insolvency risk and gives marginal financial flexibility. Over months, lower leverage eases interest burden and improves ability to secure funding or partnerships without immediate refinancing pressure.

Material Gross Margin RecoveryA sustained jump to roughly 60% gross margin indicates stronger unit economics from product mix or cost efficiency. That structural margin improvement supports future operating leverage if revenue stabilizes, making profitability achievable with disciplined expense scaling over the medium term.

Niche Digital Maternal And Fetal Health FocusHeraMED's focus on maternal/fetal remote monitoring aligns with durable trends in telehealth and home-care adoption. Specialized devices plus software and clinical decision support create stickiness with providers and potential recurring revenue, supporting long-term market positioning.

Bears Say

Persistent Negative Operating/free Cash FlowConsistent annual operating and free cash flow deficits show the business consumes cash to run. Over 2–6 months this raises funding and dilution risk, constraining investment in sales, R&D, or commercialization and making the company reliant on external capital to sustain operations.

Revenue Volatility And Recent ContractionDeclining and unstable top-line growth undermines the path to scale and to leverage the improved gross margins. Structural revenue weakness increases probability that operating losses persist, delaying breakeven and reducing the effectiveness of any fixed-cost absorption over the medium term.

Thin Equity Cushion After Prior ShrinkageA small and shrinking equity base leaves limited capital to absorb further losses or to fund growth organically. While leverage is low, the minimal buffer raises liquidity risk and increases likelihood of dilution or external financing needs if operational performance does not improve.

HeraMED Ltd. News

HeraMED Director’s Options Lapse, Slightly Reducing Future Equity Exposure

HeraMED Ltd. ( ($AU:HMD) ) has provided an update. HeraMED Ltd has reported a change in director Timothy...

2d ago

HeraMED Options Expire, Simplifying ASX-Listed Medtech’s Capital Structure

An update from HeraMED Ltd. ( ($AU:HMD) ) is now available. HeraMED Ltd has confirmed the expiry of...

2d ago

HeraMED Pilot with Lee Health Validates Digital-First Prenatal Care Model

HeraMED Ltd. ( ($AU:HMD) ) has issued an update. HeraMED has completed Phase 1 of its Digital Pregnancy...

12d ago

HeraMED Issues 15 Million Unquoted Options in Capital Management Move

An update from HeraMED Ltd. ( ($AU:HMD) ) is now available. HeraMED Ltd. has notified the market of...

1M ago

HeraMED Issues 4 Million Unquoted Options in New Equity Class

HeraMED Ltd. ( ($AU:HMD) ) has provided an announcement. HeraMED Ltd. has notified the market of the issue...

1M ago

HeraMED Seeks ASX Quotation for 1.15 Million New Shares

An announcement from HeraMED Ltd. ( ($AU:HMD) ) is now available. HeraMED Limited has applied to the Australian...

1M ago

HeraMED Wins Strong Shareholder Backing as All AGM Resolutions Pass

HeraMED Ltd. ( ($AU:HMD) ) has shared an update. HeraMED shareholders have backed the company’s strategic and governance...

2M ago

HeraMED Adds 2.5 Million Shares to ASX Quotation

HeraMED Ltd. ( ($AU:HMD) ) just unveiled an update. HeraMED Ltd. has applied to the ASX for quotation...

3M ago

HeraMED Accelerates U.S. Push as Philips Partnership and Lee Health Pilot Gain Traction

The latest announcement is out from HeraMED Ltd. ( ($AU:HMD) ). HeraMED has reported a pivotal March 2026...

3M ago

HeraMED Director Timothy Chapman Granted 2.5 Million Performance Rights

HeraMED Ltd. ( ($AU:HMD) ) has shared an update. HeraMED Ltd. has disclosed a change in director Timothy...

3M ago

HMD FAQ

What was HeraMED Ltd.’s price range in the past 12 months?

HeraMED Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.

What is HeraMED Ltd.’s market cap?

HeraMED Ltd.’s market cap is AU$42.87M.

When is HeraMED Ltd.’s upcoming earnings report date?

HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 26 days.

How were HeraMED Ltd.’s earnings last quarter?

HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.

Is HeraMED Ltd. overvalued?

According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HeraMED Ltd. pay dividends?

HeraMED Ltd. does not currently pay dividends.

What is HeraMED Ltd.’s EPS estimate?

HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HeraMED Ltd. have?

HeraMED Ltd. has 1,158,636,600 shares outstanding.

What happened to HeraMED Ltd.’s price movement after its last earnings report?

HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.

Which hedge fund is a major shareholder of HeraMED Ltd.?

Currently, no hedge funds are holding shares in AU:HMD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HeraMED Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-68.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HeraMED Ltd.

HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.